The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Investigation of synergistic effects in trials of combination therapies with immune-checkpoint inhibitors in advanced gastric or gastroesophageal junction cancer.
 
Jun Okui
Employment - Sumitomo Pharma Co., Ltd. (I)
 
Kengo Nagashima
Consulting or Advisory Role - Kowa; Lilly (Inst); Senju Pharmaceutical; Toray Industries
 
Satoru Matsuda
Honoraria - Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo/Lilly; Ethicon; MSD; Olympus Medical Systems; Ono Pharmaceutical
 
Yasunori Sato
Honoraria - Lilly Japan
Consulting or Advisory Role - Mochida Pharmaceutical Co. Ltd.
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Masashi Takeuchi
No Relationships to Disclose
 
Kenro Hirata
Honoraria - Bristol-Myers Squibb Company; Eli Lilly Japan K.K.; Ono Pharmaceutical; Taiho Pharmaceutical; Yakult Honsha
Research Funding - Ono Pharmaceutical; Taiho Pharmaceutical
 
Kai Tsugaru
No Relationships to Disclose
 
Shun Yamamoto
Honoraria - Bristol-Myers Squibb Japan; Merck Sharp and Dohme; Ono Pharmaceutical; Taiho Pharmaceutical
 
Motoo Nomura
Honoraria - Bristol-MyersSquibbK.K.; MSD; ONOPHARMACEUTICALCO.,LTD.
Consulting or Advisory Role - ONOPHARMACEUTICALCO.,LTD.
 
Takahiro Tsushima
Honoraria - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
 
Hiroya Takeuchi
Honoraria - Bristol-Myers Squibb Japan; Daiichi Sankyo/Astra Zeneca; EA Pharma; Intuitive Surgical; Johnson & Johnson/MedTech; Kaken Pharmaceutical; Medicon; Medtronic; Miyarisan pharmaceutical; MSD K.K; Nihonkayaku; Novartis; Olympus Medical Systems; Ono Pharmaceutical; Otsuka; Sysmex; Taiho Pharmaceutical; Tsumura & Co.
Research Funding - Chugai Pharma (Inst); Kaken Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Tanabe Mitsubishi Pharmaceutical (Inst)
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; Astellas Pharma; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Eisai; Ethicon; Intuitive Surgical; Japan Lifeline Co.,Ltd.; Kaken Pharmaceutical; Kowa; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smart Hospital Inc.; Sysmex; T-PEC CORPORATION; Taiho Pharmaceutical; Takeda; Toray Industries; TSUMURA & CO.
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)